# Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)

> **NCT02397928** · PHASE2 · COMPLETED · sponsor: **NovoCure Ltd.** · enrollment: 82 (actual)

## Conditions studied

- Malignant Pleural Mesothelioma

## Interventions

- **DEVICE:** NovoTTF-100L device
- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin or Carboplatin

## Key facts

- **NCT ID:** NCT02397928
- **Lead sponsor:** NovoCure Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2018-04
- **Final completion:** 2018-04
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2018-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02397928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02397928, "Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02397928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*